Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 8/20 | 1.00 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.81 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22794538 | 0.99 | PBRM1 (0.98) | PBRM1SMARCA4SMARCA2POLBMAPT | |
| SCHEMBL22794478 | 0.90 | PBRM1 (1.00) | PBRM1SMARCA4SMARCA2POLBMAPT | |
| SCHEMBL22794546 | 0.90 | PBRM1 (0.81) | PBRM1SMARCA4SMARCA2POLBMAPT | |
| SCHEMBL22794483 | 0.87 | PBRM1 (1.00) | PBRM1SMARCA4SMARCA2POLBMAPT | |
| SCHEMBL25110160 | 0.86 | PBRM1 (0.74) | PBRM1SMARCA4SMARCA2POLBMAPT | |
| SCHEMBL22794484 | 0.83 | PBRM1 (0.71) | PBRM1SMARCA4SMARCA2POLBCCR3 | |
| SCHEMBL22794560 | 0.81 | SMARCA4 (1.00) | PBRM1SMARCA4SMARCA2MAPTMAPK1 | |
| SCHEMBL22794545 | 0.81 | PBRM1 (1.00) | PBRM1SMARCA4SMARCA2POLBCCR3 | |
| SCHEMBL29801517 | 0.81 | PBRM1 (1.00) | PBRM1SMARCA4SMARCA2POLBCCR3 | |
| SCHEMBL22794557 | 0.80 | SMARCA4 (1.00) | PBRM1SMARCA4SMARCA2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251969-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PBRM1 11/4885SMARCA4 5/4885SMARCA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.